Q BioMed Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.0007
- Today's High:
- $0.001
- Open Price:
- $0.0007
- 52W Low:
- $0.0002
- 52W High:
- $0.036
- Prev. Close:
- $0.0002
- Volume:
- 117260
Company Statistics
- Market Cap.:
- $29019
- Book Value:
- -0.087
- Revenue TTM:
- $209293
- Operating Margin TTM:
- -1302.56%
- Gross Profit TTM:
- $-8988
- Profit Margin:
- -231.77%
- Return on Assets TTM:
- -85.13%
- Return on Equity TTM:
- 0%
Company Profile
Q BioMed Inc had its IPO on under the ticker symbol QBIO.
The company operates in the Healthcare sector and Biotechnology industry. Q BioMed Inc has a staff strength of 0 employees.
Stock update
Shares of Q BioMed Inc opened at $0 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0 - $0, and closed at $0.
This is a +400% increase from the previous day's closing price.
A total volume of 117,260 shares were traded at the close of the day’s session.
In the last one week, shares of Q BioMed Inc have slipped by -56.52%.
Q BioMed Inc's Key Ratios
Q BioMed Inc has a market cap of $29019, indicating a price to book ratio of 330.4621 and a price to sales ratio of 2.5478.
In the last 12-months Q BioMed Inc’s revenue was $209293 with a gross profit of $-8988 and an EBITDA of $-2676170. The EBITDA ratio measures Q BioMed Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Q BioMed Inc’s operating margin was -1302.56% while its return on assets stood at -85.13% with a return of equity of 0%.
In Q1.6666666666667, Q BioMed Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 88.1%.
Q BioMed Inc’s PE and PEG Ratio
- Forward PE
- 109.8901
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $0 per share while it has a forward price to earnings multiple of 109.8901 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Q BioMed Inc’s profitability.
Q BioMed Inc stock is trading at a EV to sales ratio of 26.6401 and a EV to EBITDA ratio of -2.0097. Its price to sales ratio in the trailing 12-months stood at 2.5478.
Q BioMed Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $3.46 million
- Total Liabilities
- $9.91 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Q BioMed Inc ended 2024 with $3.46 million in total assets and $0 in total liabilities. Its intangible assets were valued at $3.46 million while shareholder equity stood at $-6441051.00.
Q BioMed Inc ended 2024 with $0 in deferred long-term liabilities, $9.91 million in other current liabilities, 133027.00 in common stock, $-68317414.00 in retained earnings and $0 in goodwill. Its cash balance stood at $23173.00 and cash and short-term investments were $23173.00. The company’s total short-term debt was $4,083,262 while long-term debt stood at $0.
Q BioMed Inc’s total current assets stands at $33981.00 while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $2.25 million and inventory worth $0.
In 2024, Q BioMed Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Q BioMed Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0
- 52-Week High
- $0.036
- 52-Week Low
- $0.0002
- Analyst Target Price
- $
Q BioMed Inc stock is currently trading at $0 per share. It touched a 52-week high of $0.036 and a 52-week low of $0.036. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0 and 200-day moving average was $0.01 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 298.7% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Q BioMed Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Q BioMed Inc., a biomedical acceleration and development company, focuses on licensing, acquiring, and providing resources to life sciences and healthcare companies. The company offers Strontium Chloride Sr-89 and Metastron, a radiopharmaceutical therapeutic for the treatment of metastatic bone cancer pain. It is also developing Man-01, that is used for the treatment of primary open angle glaucoma; QBM-001 for rare pediatric non-verbal autism spectrum disorder; and Uttroside-B, a novel chemotherapeutic for liver cancer. Q BioMed Inc. has a partnership with Mannin Research Inc. for the development of therapeutic drugs to treat acute respiratory distress syndrome, glaucoma, kidney diseases, and others. The company was formerly known as ISMO Tech Solutions, Inc. and changed its name to Q BioMed Inc. in July 2015. Q BioMed Inc. was incorporated in 2013 and is based in New York, New York.